BERKELEY, CA, April 29, 1998--BioTime, Inc. (NASDAQ:BTIM) announced today that its common shares have been approved for listing and would begin trading today on the Nasdaq National Market under the symbol BTIM.

The Company's shares previously traded on the Nasdaq SmallCap Market and on the Boston Stock Exchange.

BioTime, headquartered in Berkeley, is engaged in the research and development of synthetic blood plasma extenders and hypothermic blood substitute solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant, and for other biomedical applications.

Contact:

BioTime, Inc.

Victoria Bellport, 510/845-9535